Could you provide insights into the clinical significance of the Phase 3 ADHERE trial results for Vyvgart Hytrulo in CIDP, particularly regarding the rapid clinical improvement and risk reduction of relapse observed compared to placebo?

The ADHERE study results suggest a significant role of IgG autoantibodies in mediating CIDP biology. How does this finding enhance our understanding of CIDP pathophysiology, and what implications does it have for future treatment approaches?

How do the deep and clinically meaningful functional improvements observed in Vyvgart Hytrulo-treated patients impact their quality of life, and what factors contribute to the high rate of treatment continuation seen in the ADHERE trial?

Argenx highlighted real-world data demonstrating the efficacy of Vyvgart and Vyvgart Hytrulo in reducing steroid use among gMG patients. Could you elaborate on the significance of this finding in optimizing treatment strategies for gMG?

Considering the observed safety and tolerability profile of Vyvgart Hytrulo in the ADHERE trial, how does it compare to other existing treatments for CIDP, and what are the key considerations for long-term management?

With the submission of data from the ADHERE trial for regulatory review, what potential impact do you foresee Vyvgart Hytrulo having on the treatment landscape for CIDP, and what are the key milestones to monitor in the coming months?

The ADHERE trial demonstrated clinical benefit across various patient subtypes, including those with prior treatment and treatment-naïve patients. How does this broad spectrum of efficacy influence treatment decisions and personalized approaches in CIDP management?

Based on the advancements showcased by Vyvgart Hytrulo, what are the emerging trends and future directions in the development of therapies for autoimmune disorders like CIDP and gMG, particularly in terms of targeted approaches and patient-centered care?